Dimethandrolone Undecanoate: A New Potent Orally Active Androgen with Progestational Activity
- 1 June 2006
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 147 (6), 3016-3026
- https://doi.org/10.1210/en.2005-1524
Abstract
Dimethandrolone (DMA), the 17beta-undecanoic acid ester of dimethandrolone (DMAU; 7alpha,11beta-dimethyl-19-nortestosterone) is a potent androgen currently in development for therapeutic uses in men. Cleavage of the 17beta-ester bond liberates the biologically active DMA. In this study we investigated the activity of DMAU and DMA both in vivo and in vitro. DMAU was active orally in castrate rat bioassays, and when administered sc, a single dose produced prolonged androgenic activity and suppression of LH with sustained circulating levels of DMA. DMA, other 19-norandrogens, and C-19 androgens bound to recombinant rat androgen receptor with high affinity and were equipotent in stimulating luciferase activity (EC50, 10(-10) -10(-9) M) in CV-1 cells cotransfected with a human androgen receptor expression vector and a luciferase reporter plasmid with three hormone response elements. Because various 19-norandrogens are also known to bind to progestin receptors (PR) and to possess progestational activity in vivo, we evaluated the binding affinity of DMA for rabbit PR and recombinant human PR-A and PR-B and its ability to induce PR-mediated transcription and endogenous alkaline phosphatase activity in T47DCO human breast cancer cells. DMA and related 19-norandrogens bound with high affinity to both rabbit and human PR, whereas the less active 11alpha-methyl stereoisomer of DMA and C-19 androgens showed low or negligible binding to PR. In T47DCO cells, 10(-8) M DMA and other 19-norandrogens stimulated transcription of a progestin/glucocorticoid/androgen response element-thymidine kinase-luciferase reporter plasmid to the same extent as R5020, the potent progestin promegestone (EC50, approximately 10(-9) M), but C-19 androgens had no effect. Antiprogestins were potent inhibitors of transactivation and alkaline phosphatase activity induced by DMA and other 19-norandrogens in T47DCO cells, whereas antiandrogens were weak inhibitors. DMA and DMAU also exhibited dose-dependent progestational activity in the estrogen-primed immature female rabbit, as assessed by induction of endometrial gland arborization. The dual androgenic and progestational activities of DMA make it a potential candidate for a single-agent male contraceptive as well as for androgen therapy in men, pending a successful outcome of pharmacokinetic and toxicity studies currently in progress.Keywords
This publication has 32 references indexed in Scilit:
- 7α,11β-Dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing propertiesBioorganic & Medicinal Chemistry Letters, 2005
- Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from the Massachusetts Male Aging StudyJournal of Clinical Endocrinology & Metabolism, 2004
- Age‐related changes in testosterone and the role of replacement therapy in older menClinical Endocrinology, 2004
- The endocrine pharmacology of testosterone therapy in menThe Science of Nature, 2004
- Progress towards hormonal male contraceptionTrends in Pharmacological Sciences, 2004
- Testosterone replacement therapy in male hypogonadismJournal of Endocrinological Investigation, 2003
- Hormone substitution in male hypogonadismMolecular and Cellular Endocrinology, 2000
- 7α-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgensThe Journal of Steroid Biochemistry and Molecular Biology, 1999
- Binding of [3H]-methyltrienolone (R1881) by human breast cancersEuropean Journal of Cancer and Clinical Oncology, 1983
- Simultaneous Measurement of Progesterone and Androgen Receptors in Human Prostate: A Microassay*Journal of Clinical Endocrinology & Metabolism, 1982